Doublet Maintenance Therapy Does Not Outperform Monotherapy in Ovarian Cancer
Physician's Weekly,
The addition of nivolumab to rucaparib maintenance therapy did not improve progression-free survival (PFS) in patients with…
The addition of nivolumab to rucaparib maintenance therapy did not improve progression-free survival (PFS) in patients with…
The following is a summary of “A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in…
A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed…